Research programme: TL1A inhibitors - Psivant Therapeutics
Latest Information Update: 09 Aug 2024
Price :
$50 *
At a glance
- Originator Psivant Therapeutics
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Tumour necrosis factor ligand superfamily member 15 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Immunological disorders; Inflammation
Most Recent Events
- 08 Aug 2024 Early research in Immunological disorders in USA (PO), before August 2024 (Psivant Therapeutics pipeline, August 2024)
- 08 Aug 2024 Early research in Inflammation in USA (PO), before August 2024 (Psivant Therapeutics pipeline, August 2024)